The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Cited by (1,044)

Items 701–800 of 1,044

1. New ideas about aldosterone signaling in epithelia
   James D. Stockand · 2002 · American Journal of Physiology-Renal Physiology
2. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease
   Chung, Edmund YM, Ruospo, Marinella, Natale, Patrizia, Bolignano, Davide, Navaneethan, Sankar D, Palmer, Suetonia C, Strippoli, Giovanni FM · 2020 · Cochrane Database of Systematic Reviews
3. An update on the management of Chagas cardiomyopathy
   Manoel OC Rocha, Mauro Martins Teixeira, Antônio Luiz Pinho Ribeiro · 2007 · Expert Review of Anti-infective Therapy
4. Electrical storm is an independent predictor of adverse long-term outcome in the era of implantable defibrillator therapy
   K. A. Gatzoulis, G ANDRIKOPOULOS, Theodoros Apostolopoulos, Elias Sotiropoulos, George Zervopoulos, Julia D. Antoniou, Stela Brili, Christodoulos Stefanadis · 2005 · EP Europace
5. Effect of spironolactone on cardiacsympathetic nerve activity and left ventricular remodeling in patients with dilated cardiomyopathy
   Shu Kasama, Takuji Toyama, Hisao Kumakura, Yoshiaki Takayama, Shûichi Ichikawa, Tadashi Suzuki, Masahiko Kurabayashi · 2003 · Journal of the American College of Cardiology
6. Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implications
   Murray Epstein · 2001 · American Journal of Kidney Diseases
7. Hyponatremia in Acute Decompensated Heart Failure
   Frederik Hendrik Verbrugge, Paul Steels, Lars Grieten, Petra Nijst, W.H. Wilson Tang, Wilfried Müllens · 2015 · Journal of the American College of Cardiology
8. Atualização de Tópicos Emergentes da Diretriz Brasileira de Insuficiência Cardíaca – 2021
   Fabiana G. Marcondes‐Braga, Lídia Zytynski Moura, Victor Sarli Issa, Jefferson Luís Vieira, Luís Eduardo Paim Rohde, Marcus Vinı́cius Simões, Miguel Morita Fernandes-Silva, Salvador Rassi, Sílvia Marinho Martins, Denílson Campos de Albuquerque et al. · 2021 · Arquivos Brasileiros de Cardiologia
9. Increased prevalence of diabetes mellitus and the metabolic syndrome in patients with primary aldosteronism of the German Conn's Registry
   Hanslik, Gregor, Wallaschofski, Henri, Dietz, Anna, Riester, Anna, Reincke, Martin, Allolio, Bruno, Lang, Katharina, Quack, Ivo, Rump, Lars C, Willenberg, Holger S et al. · 2015 · European Journal of Endocrinology
10. Tissue-specific modulation of mineralocorticoid receptor function by 11β-hydroxysteroid dehydrogenases: An overview
    Alex Odermatt, Denise V. Kratschmar · 2011 · Molecular and Cellular Endocrinology
11. Predictors of Hyperkalemia Risk following Hypertension Control with Aldosterone Blockade
    Nitin Khosla, Rigas Kalaitzidis, George L. Bakris · 2009 · American Journal of Nephrology
12. Differences Between General Practitioners and Cardiologists in Diagnosis and Management of Heart Failure: A Survey in Every-Day Practice
    Frans Hendrik Rutten, Diederick E. Grobbee, Arno Wilhelmus Hoes · 2003 · European Journal of Heart Failure
13. Myocardial Fibrosis in DOCA-Salt Hypertensive Rats
    Fatima Ammarguellat, Isabelle Larouche, Ernesto L. Schiffrin · 2001 · Circulation
14. The Path to an Angiotensin Receptor Antagonist-Neprilysin Inhibitor in the Treatment of Heart Failure
    Eugene Braunwald M. D · 2015 · Journal of the American College of Cardiology
15. Echocardiographic Assessment of Left Ventricular Systolic Function: An Overview of Contemporary Techniques, Including Speckle-Tracking Echocardiography
    Sushil Allen Luis, Jonathan H. Chan, Patricia A. Pellikka · 2019 · Mayo Clinic Proceedings
16. Therapy With Cardiac Contractility Modulation Electrical Signals Improves Left Ventricular Function and Remodeling in Dogs With Chronic Heart Failure
    Makoto Imai, Sharad Rastogi, Ramesh C. Gupta, Sudhish Mishra, Victor G. Sharov, William C. Stanley, Yuval Mika, Benny Rousso, Daniel Burkhoff, Shlomo A. Ben‐Haim et al. · 2007 · Journal of the American College of Cardiology
17. Long-Term Mortality with Cardiac Resynchronization Therapy in the Cardiac Resynchronization-Heart Failure (CARE-HF) Trial
    John G.F. Cleland, Nick Freemantle, Erland Erdmann, Daniel Gras, LUKAS J. KAPPENBERGER, Luigi Tavazzi, Jean‐Claude Daubert · 2012 · European Journal of Heart Failure
18. The Euro Heart Failure Survey of The EUROHEART Survey Programme: A Survey on the Quality of Care Among Patients with Heart Failure in Europe
    John G.F. Cleland, Karl B Swedberg, Alain Cohen Solal, Juan Cosín‐Aguilar, Rainer Dietz, Ferenc Folláth, Antonello Gavazzi, Richard F. Hobbs, J Korewicki, Hugo Costa Madeira et al. · 2000 · European Journal of Heart Failure
19. The renin-angiotensin-aldosterone system (RAAS) and cardiac arrhythmias
    Shahriar Iravanian, Samuel C. Dudley · 2008 · Heart Rhythm
20. Management of hypertensive crises: the scientific basis for treatment decisions
    Jon D. Blumenfeld · 2001 · American Journal of Hypertension
21. Diuretics for heart failure
    Rajaa F Faris, Marcus D Flather, Henry Purcell, Philip Alexander Poole-Wilson, Andrew J.S. Coats · 2012 · Cochrane Database of Systematic Reviews · Retracted
22. Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
    Peter Kolkhof, Steffen A. Borden · 2011 · Molecular and Cellular Endocrinology
23. The relationship between vitamin D and the renin-angiotensin system in the pathophysiology of hypertension, kidney disease, and diabetes
    Vaidya, Anand, Williams, Jonathan S. · 2012 · Metabolism
24. Salt, aldosterone, and insulin resistance: impact on the cardiovascular system
    Guido Lastra, Sonal Dhuper, Megan S. Johnson, James R. Sowers · 2010 · Nature Reviews Cardiology
25. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance
    Zaid A. Abassi, Tony Karram, Samer Ellaham, Joseph M. Winaver, Aaron Hoffman · 2004 · Pharmacology & Therapeutics
26. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction
    Johann K Bauersachs, Marina Heck, Daniela Fraccarollo, Steven K. Hildemann, Georg Ertl, Martin Wehling, Michael Christ · 2002 · Journal of the American College of Cardiology
27. Cardiac Fibrosis and Arrhythmogenesis
    My‐Nhan Nguyen, Helen Kiriazis, Xiao‐Ming Gao, Xiao‐Jun Du · 2017 · Comprehensive physiology
28. Role of Rac1–mineralocorticoid-receptor signalling in renal and cardiac disease
    Miki Nagase, Toshiro Fujita · 2013 · Nature Reviews Nephrology
29. Cardiovascular disease in chronic kidney disease
    Katharina Marx-Schütt, David Z.I. Cherney, Joachim Jankowski, Kunihiro Matsushita, Massimo Nardone, Nikolaus Marx · 2025 · European Heart Journal
30. Clinical Implications of Physiological Changes in the Aging Heart*
    Kenneth G. Pugh, Jeanne Y. Wei · 2001 · Drugs & Aging
31. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure
    Joseph Francis, Robert M. Weiss, Shun‐Guang Wei, Alan Kim Johnson, Terry G. Beltz, Kathy Zimmerman, Robert B. Felder · 2001 · American Journal of Physiology-Heart and Circulatory Physiology
32. 50th Anniversary of Aldosterone
    Jonathan S. Williams, Gordon H. Williams · 2003 · The Journal of Clinical Endocrinology & Metabolism
33. Drug-Induced Hyperkalemia
    Chaker Ben Salem, Atef Badreddine, Neila Fathallah, Raoudha Slim, Houssem Hmouda · 2014 · Drug Safety
34. Torcetrapib Induces Aldosterone and Cortisol Production by an Intracellular Calcium-Mediated Mechanism Independently of Cholesteryl Ester Transfer Protein Inhibition
    Xiao Hu, Jessica D. Dietz, Chunsheng Xia, Delvin R. Knight, William Loging, Andrew H. Smith, Haodan Yuan, David A. Perry, Joan A. Keiser · 2009 · Endocrinology
35. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction
    Jordan B. King, Rashmee U. Shah, Adam Phillip Bress, Richard E. Nelson, Brandon Kyle Bellows · 2016 · JACC Heart Failure
36. Clinical Phenotypes of Fontan Failure: Implications for Management
    Wendy Book, Jennifer F. Gerardin, Anita P. Saraf, Anne Marie Valente, Fred H. Rodriguez · 2016 · Congenital Heart Disease
37. Renal Effects of Guideline-Directed Medical Therapies in Heart Failure: A Consensus Document from the Heart Failure Association of the European Society of Cardiology
    Wilfried Müllens, Pieter Martens, Jeffrey Moore Testani, W.H. Wilson Tang, Hadi N. Skouri, Frederik Hendrik Verbrugge, Marat Fudim, Massimo Iacoviello, Jennifer Franke, Andreas J. Flammer et al. · 2022 · European Journal of Heart Failure
38. Aldosterone Escape during Angiotensinconverting Enzyme Inhibitor Therapy in Essential Hypertensive Patients with Left Ventricular Hypertrophy
    Akira Sato, Takao Saruta · 2001 · Journal of International Medical Research
39. Rationale and design of a study assessing treatment strategies of atrial fibrillation in patients with heart failure: The Atrial Fibrillation and Congestive Heart Failure (AF-CHF) trial
    The AF-CHF Trial Investigators · 2002 · American Heart Journal
40. Hypertension in Obesity and the Impact of Weight Loss
    Cohen, Jordana B. · 2017 · Current Cardiology Reports
41. Aldosterone Stimulates Matrix Metalloproteinases and Reactive Oxygen Species in Adult Rat Ventricular Cardiomyocytes
    Mary Katherine Rude, Toni-Ann S. Duhaney, Gabriela M. Kuster, Sharon Judge, Joline Heo, Wilson S. Colucci, Deborah A. Siwik, Flora Sam · 2005 · Hypertension
42. Novel RAAS agonists and antagonists: clinical applications and controversies
    César A. Romero, Marcelo Orías, Matthew R. Weir · 2015 · Nature Reviews Endocrinology
43. Vein graft failure
    Christopher D. Owens, Warren J. Gasper, Amreen S. Rahman, Michael S. Conte · 2013 · Journal of Vascular Surgery
44. Impact of Practice-Based Management of Pulmonary Artery Pressures in 2000 Patients Implanted With the CardioMEMS Sensor
    James Thomas Heywood, Rita A. Jermyn, David M. Shavelle, William T. Abraham, Arvind Bhimaraj, Kunjan A. Bhatt, Fareed Sheikh, Eric J. Eichhorn, Sumant Lamba, Rupinder Bharmi et al. · 2017 · Circulation
45. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity
    I Guerrero Feria, Israel Pichardo, Patricia Juárez, Victoria Ramírez, Marco A. González, Norma Uribe, Romeo García-Torres, Fernando López‐Casillas, Gerardo Gamba, Norma Araceli Bobadilla · 2003 · Kidney International
46. Associations of Gender and Etiology With Outcomes in Heart Failure With Systolic Dysfunction
    Camille G. Frazier‐Mills, Karen P. Alexander, Laura Kristin Newby, Susan Anderson, Erik R Iverson, Milton Packer, Jay N. Cohn, Sidney Goldstein, Pamela S. Douglas · 2007 · Journal of the American College of Cardiology
47. Type 2 diabetes mellitus and heart failure, a scientific statement from the American Heart Association and Heart Failure Society of America
    Dunlay, Shannon M., Givertz, Michael M., Aguilar, David, Allen, Larry A., Chan, Michael, Desai, Akshay S., Deswal, Anita, Dickson, Victoria Vaughan, Kosiborod, Mikhail N., Lekavich, Carolyn L. et al. · 2019 · Journal of Cardiac Failure
48. Congestive Renal Failure: The Pathophysiology and Treatment of Renal Venous Hypertension
    Edward A. Ross · 2012 · Journal of Cardiac Failure
49. Heart Failure in Older Adults
    Hoda Butrous, Scott L. Hummel · 2016 · Canadian Journal of Cardiology
50. Trends in Death Attributed to Heart Failure Over the Past Two Decades in Europe
    Sai͏̈d Laribi, Albertine Aouba, Maria Nikolaou, Johan P.E. Lassus, Alain Cohen Solal, Patrick I. Plaisance, Gérard Pavillon, Preeti Jois, Gregg C. Fonarow, Éric Jougla et al. · 2012 · European Journal of Heart Failure
51. Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes
    Jagadish Khanagavi, Tanush Gupta, Wilbert S. Aronow, Tushar M. Shah, Jalaj Garg, Chul Woo Ahn, Sachin S. Sule, Stephen Peterson · 2014 · Archives of Medical Science
52. Primary and Secondary Prevention of Cardiovascular Diseases: A Practical Evidence-Based Approach
    James Henry O’Keefe, Maia D. Carter, Carl J. Lavie · 2009 · Mayo Clinic Proceedings
53. Ablation of Mineralocorticoid Receptors in Myocytes But Not in Fibroblasts Preserves Cardiac Function
    Achim Lother, Stefan Berger, Ralf Gilsbach, Stephan Rösner, Andreas Ecke, Frederico Barreto, Johann K Bauersachs, Günther Schütz, Lutz Hein · 2011 · Hypertension
54. Furosemide and the progression of left ventricular dysfunction in experimental heart failure
    John M. McCurley, Stephen U. Hanlon, Shao-kui Wei, Erich F. Wedam, Michael Michalski, Mark C. Haigney · 2004 · Journal of the American College of Cardiology
55. A pilot experience with permanent biventricular pacing to treat advanced heart failure
    Christophe Leclercq, Serge Cazeau, Philippe Ritter, Christine Alonso, Daniel Gras, Philippe Mabo, Arnaud Lazarus, Jean‐Claude Daubert · 2000 · American Heart Journal
56. Diuretics for Hypertension: A Review and Update
    Roush, George C., Sica, Domenic A. · 2016 · American Journal of Hypertension
57. Reconsidering the Roles of the Mineralocorticoid Receptor
    John W. Funder · 2009 · Hypertension
58. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone
    Juan Manuel Mejia-Vilet, Victoria Ramírez, Cristino Cruz, Norma Uribe, Gerardo Gamba, Norma Araceli Bobadilla · 2007 · American Journal of Physiology-Renal Physiology
59. Therapeutic Targets in Heart Failure
    Erik B. Schelbert, Gregg C. Fonarow, Robert O. Bonow, Javed Butler, Mihai Gheorghiade · 2014 · Journal of the American College of Cardiology
60. Management of Low Blood Pressure in Ambulatory Heart Failure with Reduced Ejection Fraction Patients
    Jennifer Cautela, Jean‐Michel Tartière, Alain Cohen Solal, Anne Bellemain-Appaix, Alexis Théron, Thierry Tibi, James L. Januzzi, François Roubille, Nicolas Girerd · 2020 · European Journal of Heart Failure
61. Control of metabolism and signaling of simple bioactive sphingolipids: Implications in disease
    Patricia Gangoiti, Luz Camacho, Lide Arana, Alberto Ouro, María H. Granado, Leyre Brizuela, Josefina Casas, Gemma Fabriàs, José Luı́s Abad, Antonio Delgado et al. · 2010 · Progress in Lipid Research
62. Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease
    Jean‐Philippe Bertocchio, David G. Warnock, Frédéric Jaisser · 2011 · Kidney International
63. Drug-induced gynecomastia: an evidence-based review
    Fnu Deepinder, Glenn David Braunstein · 2012 · Expert Opinion on Drug Safety
64. Associations Between Aldosterone Antagonist Therapy and Risks of Mortality and Readmission Among Patients With Heart Failure and Reduced Ejection Fraction
    Adrian F. Hernandez, Xiaojuan Mi, Bradley G. Hammill, Stephen C. Hammill, Paul A. Heidenreich, Frederick A. Masoudi, Laura Goettinger Qualls, Eric David Peterson, Gregg C. Fonarow, Lesley H. Curtis · 2012 · JAMA
65. Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony
    Friedrich M Fruhwald, Astrid Fahrleitner‐Pammer, Rudolf Berger, Francisco Leyva, Nick Freemantle, Erland Erdmann, Daniel Gras, Lukas Kappenberger, Luigi Tavazzi, Jean‐Claude Daubert et al. · 2007 · European Heart Journal
66. Micronutrient Deficiencies
    Victor Soukoulis, Jamil B. Dihu, Michael J. Sole, Stefan D. Anker, John G.F. Cleland, Gregg C. Fonarow, Marco Metra, Evasio Pasini, Theresa A. Strzelczyk, Heinrich Taegtmeyer et al. · 2009 · Journal of the American College of Cardiology
67. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: a randomized controlled study
    Rita Rachmani, Inna Slavachevsky, M Amit, Zohar Levi, Yoav Kedar, Maya Berla, Mordchai Ravid · 2004 · Diabetic Medicine · Retracted
68. Variability in the Renin/Aldosterone Profile under Random and Standardized Sampling Conditions in Primary Aldosteronism
    Akiyo Tanabe, Mitsuhide Naruse, Sachiko Takagi, Ken Tsuchiya, Toshihiro Imaki, Kazue Takano · 2003 · The Journal of Clinical Endocrinology & Metabolism
69. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment
    J E Macdonald, N Kennedy, A D Struthers · 2004 · Heart
70. Extracellular matrix remodeling in atrial fibrosis: Mechanisms and implications in atrial fibrillation
    Jason Pellman, Robert C. Lyon, Farah Sheikh · 2009 · Journal of Molecular and Cellular Cardiology
71. Antagonists of Aldosterone and Proteinuria in Patients With CKD: An Uncontrolled Pilot Study
    Stefano Bianchi, Roberto Bigazzi, Vito M. Campese · 2005 · American Journal of Kidney Diseases
72. The Role of Calmodulin Kinase II in Myocardial Physiology and Disease
    Luis F. Couchonnal, Mark E. Anderson · 2008 · Physiology
73. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
    Milton Packer, Stefan D. Anker, Javed Butler, Gerasimos S Filippatos, João Pedro Ferreira, Stuart Pocock, Hans‐Peter Brunner‐La Rocca, Stefan P. Janssens, Hiroyuki Tsutsui, Jian Zhang et al. · 2020 · European Heart Journal
74. Disorders of Potassium
    Timothy J. Schaefer, Robert W. Wolford · 2005 · Emergency Medicine Clinics of North America
75. Challenges and opportunities for primary, secondary, and tertiary prevention of Chagas’ disease
    Anis Rassi, João Carlos Pinto Dias, José Antônio Marin‐Neto, Anis Rassi · 2009 · Heart
76. Critical Care Nephrology
    John A. Kellum, Rinaldo Bellomo, Claudio Ronco · 2012 · Elsevier eBooks
77. Early Aldosterone Blockade in Acute Myocardial Infarction
    Farzin Beygui, Guillaume Cayla, Vincent Roule, François Roubille, Nicolas Delarche, Johanne Silvain, Eric VAN BELLE, Loïc Belle, Michel Galinier, Pascal Motreff et al. · 2016 · Journal of the American College of Cardiology
78. Diabetes Mellitus, the Renin-Angiotensin-Aldosterone System, and the Heart
    Hoong Sern Lim, Robert J. MacFadyen, Gregory Y.H. Lip · 2004 · Archives of Internal Medicine
79. The STICH Trial (Surgical Treatment for Ischemic Heart Failure)
    Peter E. Carson, JOHN H. WERTHEIMER, Alan Bruce Miller, Christopher M. O’Connor, Ileana L. Piña, Craig H. Selzman, Carla A. Sueta, Lilin She, Deborah Greene, Kerry L. Lee et al. · 2013 · JACC Heart Failure
80. Low-dose spironolactone in the management of resistant hypertension: a surveillance study
    Deirdre A. Lane, Sarah Shah, D. Gareth Beevers · 2007 · Journal of Hypertension
81. Cardiac resynchronization therapy: a meta-analysis of randomized controlled trials
    George A. Wells, Ratika Parkash, Jeff S. Healey, Mario R. Talajic, J. Malcolm O. Arnold, S. Sullivan, J. Peterson, Elizabeth Yetisir, Patricia Theoret-Patrick, M. Luce et al. · 2011 · Canadian Medical Association Journal
82. Management of patients with diabetes and CKD: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference
    Vlado Perkovic, Rajiv Agarwal, Paola Fioretto, Brenda R. Hemmelgarn, Adeera Levin, Merlin C. Thomas, Christoph Wanner, B.L. Kasiske, David Collins. Wheeler, Per‐Henrik Groop et al. · 2016 · Kidney International
83. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
    Kiyoshi Arai, Tsuyoshi Homma, Yuka Morikawa, Naoko Ubukata, Hiyoyuki Tsuruoka, Kazumasa Aoki, Hirokazu Ishikawa, Makoto Mizuno, Toshio Sada · 2015 · European Journal of Pharmacology
84. Aldosterone in Chronic Kidney and Cardiac Disease
    Thomas H. Hostetter, Hassan N. Ibrahim · 2003 · Journal of the American Society of Nephrology
85. Is There an Unrecognized Epidemic of Primary Aldosteronism? (Pro)
    David A. Calhoun · 2007 · Hypertension
86. Association Between Diffuse Myocardial Fibrosis by Cardiac Magnetic Resonance Contrast-Enhanced T 1 Mapping and Subclinical Myocardial Dysfunction in Diabetic Patients
    Arnold C.T. Ng, Dominique Auger, Victoria Delgado, Saskia G. C. van Elderen, Matteo Bertini, Hans-Marc Siebelink, Rob J. van der Geest, Cosimo Bonetti, Enno Tjeerd van der Velde, A. Roos et al. · 2011 · Circulation Cardiovascular Imaging
87. 2015 ESC Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting Without Persistent ST-segment Elevation
    Marco Roffi, Carlo Patrono, Jean‐Philippe Collet, Christian Eugen Mueller, Marco Valgimigli, Felicita Andreotti, Jeroen Joost Bax, Michael Andrew Borger, Carlos Brotons, Derek P. Chew et al. · 2015 · Revista Española de Cardiología (English Edition)
88. Chronic Kidney Disease as a Comorbidity in Heart Failure
    Magdalena Szlagor, Jill Dybiec, Ewelina Młynarska, Jacek Rysz, Beata Franczyk · 2023 · International Journal of Molecular Sciences
89. The Adequacy of Laboratory Monitoring in Patients Treated With Spironolactone for Congestive Heart Failure
    Keyur B. Shah, Krishnamurti Rao, Robert Sawyer, Stephen S. Gottlieb · 2005 · Journal of the American College of Cardiology
90. Long-term retention of cardiac resynchronization therapy
    Bradley P. Knight, Aseem D. Desai, James A. Coman, Mitchell N. Faddis, Patrick Yong · 2004 · Journal of the American College of Cardiology
91. How to write an evidence-based clinical review article.
    Jay Siwek, Margaret L. Gourlay, David C. Slawson, Allen F. Shaughnessy · 2002 · PubMed
92. Endothelial Cell Mineralocorticoid Receptors Regulate Deoxycorticosterone/Salt-Mediated Cardiac Remodeling and Vascular Reactivity But Not Blood Pressure
    Amanda J. Rickard, James Morgan, Sophocles Chrissobolis, Alyson A. Miller, Christopher Graeme Sobey, Morag J. Young · 2014 · Hypertension
93. Aldosterone as a cardiovascular risk factor
    Gian Paolo Rossi, Marco Boscaro, Vanessa Ronconi, John W. Funder · 2005 · Trends in Endocrinology and Metabolism
94. Glucocorticoid-mediated mineralocorticoid receptor activation and hypertension
    Felix Julius Frey, Alex Odermatt, Brigitte M. Frey · 2004 · Current Opinion in Nephrology & Hypertension
95. Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Effect of Aldosterone Antagonism With Eplerenone on Ventricular Remodeling in Patients With Mild-to-Moderate Heart Failure and Left Ventricular Systolic Dysfunction
    James E. Udelson, Arthur Michael Feldman, Barry Greenberg, Bertram Pitt, Robin Mukherjee, Henry A. Solomon, Marvin A. Konstam · 2010 · Circulation Heart Failure
96. Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype
    Mariantonietta Cicoira, Luisa Zanolla, Andrea Rossi, Giorgio Golia, Lorenzo Franceschini, Giulio Cabrini, Alberto Bonizzato, Maristella Graziani, Stefan D. Anker, Andrew J.S. Coats et al. · 2001 · Journal of the American College of Cardiology
97. The Oxidative Stress Hypothesis of Congestive Heart Failure
    Susanna S Mak, Gary E. Newton · 2001 · CHEST Journal
98. Cardiac Damage Prevention by Eplerenone: Comparison With Low Sodium Diet or Potassium Loading
    Diego Martinez-Vasquez, Ricardo Rocha, Mamiko Matsumura, Eveline M. Oestreicher, Margarita R. Ochoa-Maya, Weranuj Roubsanthisuk, Gordon H. Williams, Gail Kurr Adler · 2002 · Hypertension
99. Renin–angiotensin–aldosterone inhibitors in the reduction of portal pressure: A systematic review and meta-analysis
    Puneeta Tandon, Juan G. Abraldeṣ, Annalisa Berzigotti, Juan Carlos García‐Pagán, Jaime Bosch · 2010 · Journal of Hepatology
100. Dual Role for Glucocorticoids in Cardiomyocyte Hypertrophy and Apoptosis
     Rongqin Ren, Robert H. Oakley, Diana Cruz‐Topete, John Anthony Cidlowski · 2012 · Endocrinology